Genetic Testing Market by Product, Test Type, Technology, Application, Distribution Channel, End-User

List of Tables

[183 Pages Report] The Genetic Testing Market size was estimated at USD 11.89 billion in 2023 and expected to reach USD 13.55 billion in 2024, at a CAGR 14.01% to reach USD 29.79 billion by 2030.

Genetic testing comprises a diverse range of products and services to analyze an individual's DNA to identify specific genes, chromosomes, or proteins linked to inherited traits, disease predispositions, or therapeutic responses. Various sectors, including clinical diagnostics, pharmaceutical research and development, biotechnology innovation, forensics, nutrigenomics, and direct-to-consumer services, are important business sectors in this market. Several factors have contributed to the significant growth of the genetic testing market in recent years. These include advancements in DNA sequencing technologies such as next-generation sequencing (NGS), increased awareness about early diagnosis benefits through genetic testing, growing prevalence of genetic disorders, an aging population, rising demand for personalized medicine, expanding use of direct-to-consumer genetic testing services, and supportive government policies coupled with favorable reimbursement scenarios. Emerging opportunities within the genetic testing market involve integrating with other cutting-edge technologies such as artificial intelligence (AI), big data analytics, and telemedicine platforms; entering high-growth markets such as Asia-Pacific; fostering public-private partnerships to bolster genomic research initiatives; applying precision medicine programs tailored to individual genetic profiles; and using liquid biopsy technology for early cancer detection via circulating tumor DNA (ctDNA) in blood samples. Nevertheless, the growth potential is hampered by several limitations and challenges that include ethical concerns regarding privacy issues and misuse of genetic information; insufficient public awareness about genetic testing's significance; affordability constraints due to high costs of advanced tests for certain segments of the population; inconsistent guidelines and regulations across countries; concerns over false results leading to misinterpretation by healthcare professionals and patients alike; and workforce shortage in areas such as certified genetic counselors.

KEY MARKET STATISTICS
Base Year [2023]	USD 11.89 billion
Estimated Year [2024]	USD 13.55 billion
Forecast Year [2030]	USD 29.79 billion
CAGR (%)	14.01%

Innovation and research efforts in the genetic testing market should be geared towards developing novel gene-editing technologies such as CRISPR-Cas9 for precision editing capabilities, enhancing bioinformatics tools for better interpretation of vast genomic data generated by high-throughput sequencing platforms, exploring new applications in non-invasive prenatal testing (NIPT) using cell-free fetal DNA (cffDNA); discovering unique biomarkers for disease conditions that can be targeted through pharmacogenomics approaches; and expanding into fields such as environmental genomics to assess individual responses to various environmental factors.

Product: Penetration of software and services for efficient data management and analysis

Consumables and equipment in the genetic testing industry include products including reagents, assay kits, lab instruments, and devices required for sample collection, processing, and analysis. This segment is indispensable for performing accurate and reliable tests across various applications. Diagnostic Laboratories require high-quality consumables including reagents and assay kits for accurate diagnosis of diseases. In addition, research institutes rely on advanced equipment including sequencers or PCR machines to study genetics at a molecular level. On the other hand, the software and services includes bioinformatics tools for data storage, management, and analysis, as well as genetic counseling and consulting services. Software and services emphasizes data management and analysis solutions that cater to the growing need for efficient handling of complex genomic data.

Test Type: Emphasis on diagnostic testing to perform particular disease dignosis

Carrier testing is conducted to identify individuals with one copy of a gene mutation responsible for a genetic disorder in their offspring when paired with another carrier. It is often recommended for couples planning to have children, especially when there is a family history of specific genetic conditions. On the other hand, diagnostic testing is performed after an individual develops disease symptoms or needs to confirm or rule out a particular diagnosis. Newborn screening tests help identify potentially life-threatening infections in newborns as early as possible to initiate prompt medical intervention. The tests usually involve blood samples taken shortly after birth and may also include hearing screenings and pulse oximetry tests for congenital heart defects. Pharmacogenomics studies show how an individual's genetic makeup affects their medication response. By understanding these differences, healthcare professionals can optimize drug therapy selection and dosing for improved treatment outcomes. Preimplantation genetic testing is performed on embryos created through in vitro fertilization (IVF) to identify congenital abnormalities before uterine implantation. The two primary types of preimplantation testing are preimplantation genetic diagnosis (PGD), which screens for specific genetic disorders, and preimplantation genetic screening (PGS), which assesses embryo chromosomal makeup. Prenatal testing helps detect potential health problems during pregnancy and includes diagnostic tests (e.g., amniocentesis) and screenings (e.g., non-invasive prenatal testing or NIPT). Presymptomatic and predictive testing identifies genetic mutations in asymptomatic individuals who may be at high risk for developing specific diseases later in life. This testing information allows individuals to make informed decisions about their health management strategies or take preventive measures to reduce disease risk.

Technology: Increasing shift toward DNA sequencing for precise gene identification and disease diagnosis

Cytogenetics is the study of chromosomal abnormalities and their role in genetic disorders. Cytogenetics technology involves analyzing the structure and number of chromosomes and identifying aberrations that may contribute to disease development. Common cytogenetic tests include karyotyping and fluorescence in situ hybridization (FISH). DNA sequencing technology decodes the precise order of nucleotides within DNA molecules to identify genes and determine their function. The need-based preference for this technology lies in its ability to diagnose hereditary conditions, detect genetic mutations in cancer cells, and guide personalized medicine approaches. Gene expression profiling measures the activity levels of thousands of genes simultaneously to understand their role in disease development or progression. Gene expression profiling technology is useful for identifying novel therapeutic targets, understanding treatment responses, and guiding personalized therapy decisions. Microarrays and RNA sequencing (RNA-seq) are commonly used techniques for gene expression profiling. Microarrays are high-throughput technology platforms that analyze gene expression or detect genetic variations such as single nucleotide polymorphisms (SNPs). Their need-based preference includes studying gene function at the genome level or screening for potential disease-related biomarkers. PCR is a widely utilized molecular biology technique for amplifying and quantifying specific DNA sequences. PCR has various applications, including genetic testing, pathogen detection, and forensic analysis. The need-based preference for PCR is its ability to generate results quickly and accurately with minimal sample material.

Application: Rising adoption of genetic testing to detect early signs of cancer

Autoimmune disorders result from an immune system dysfunction, leading it to attack the body's cells and tissues. Genetic testing is crucial in identifying genetic predispositions for these conditions, enabling early detection and targeted treatment plans. A comprehensive understanding of an individual's genetic makeup can help detect early signs of cancer or identify familial risks, allowing for personalized prevention strategies and targeted therapies. Heart disease, diabetes, and obesity have complex interplays between environmental factors and genetics. Genetic testing assists in determining an individual's susceptibility to these conditions and helps develop tailored lifestyle interventions or medication plans to reduce risks. Cystic fibrosis, muscular dystrophy, and thalassemia are caused by mutations in specific genes. Genetic testing enables accurate diagnosis of genetic disorders and allows carrier screening to identify at-risk couples planning to have children. Neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's, can have strong genetic links. Genetic testing helps uncover predispositions to these conditions, enabling preventive measures or early interventions to slow disease progression.

Distribution Channel: Deployment of genetic testing products on online platforms

Offline distribution includes traditional brick-and-mortar establishments such as hospitals, clinics, and diagnostic laboratories, catering to individuals seeking personalized guidance through face-to-face interactions with healthcare professionals. The main benefits of offline distribution are direct consultation with medical experts, secure sample collection protocols, comprehensive insurance coverage options, and immediate access to follow-up care if needed. Online distribution represents a rapidly growing segment in the genetic testing market that appeals to tech-savvy individuals seeking convenient access to services from home. Major direct-to-consumer (DTC) brands predominantly offer ancestry or health-related tests through websites or eCommerce platforms. Advantages of online genetic testing include ease of use (sample collection kits mailed directly to users), quick turnaround times, cost-effectiveness, and access to a wide range of tests. However, it may lack personalized medical support available through offline channels. Ultimately, the choice between offline and online distribution depends on individual preferences and needs.

End-User: Extensive use of genetic testing solutions in hospitals & clinics for disease diagnosis and treatment planning

Diagnostic laboratories play a pivotal role in genetic testing due to their specialized services and extensive range of tests. Home-setting genetic testing is gaining popularity owing to the growing demand for direct-to-consumer (DTC) tests that provide insights into ancestry, health risks, and personal traits. Hospitals and clinics form another essential part of the end-user landscape as they integrate genetic testing services into patient care pathways for disease diagnosis and treatment planning. Hospitals have started incorporating pharmacogenomic testing to help tailor medication selection based on the patient's genetic makeup.

Regional Insights

The advanced healthcare infrastructure and strong government support for research and development in the Americas have led to a thriving genetic testing market. However, regulatory challenges remain as manufacturers must adhere to strict guidelines set by agencies such as the Food Drug Administration (FDA). Europe presents a diverse landscape with varying regulations across its member countries. The UK's Brexit has caused uncertainty in its regulatory framework. Manufacturers or providers must tailor their strategies to each country's specific requirements. The Middle East & Africa have potential for genetic testing providers due to growing populations and the increasing prevalence of chronic diseases. However, limited healthcare infrastructure and a lack of awareness about genetic testing services create challenges for entry into these markets. The APAC region offers major growth opportunities within China, Japan, and India as their large patient populations require accurate diagnosis and proactive management of hereditary conditions. Despite regulatory hurdles similar to those in developed countries, there is room for innovation catering to local context needs. Genetic testing is becoming vital to personalized medicine and preventive healthcare in developed countries; however, navigating complex regulations is crucial. In emerging countries, where potential lies for market expansion investment in local partnerships, educational initiatives, and infrastructure development. Recent news highlights collaborations aimed at improving offerings within the genetic testing market. Global genetic testing offers numerous opportunities to stay informed about regional trends and adapt strategies accordingly, ultimately contributing meaningfully to public health outcomes worldwide.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Genetic Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Genetic Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Blueprint Genetics Oy, Centogene N.V., Color Health, Inc., CooperSurgical Inc., Editas Medicine, Inc., ELITechGroup SAS, Eugene Labs Pty Ltd., Eurofins Scientific SE, F. Hoffmann-La Roche AG, Fulgent Genetics, Inc., Gene by Gene, Ltd., GeneDx, LLC, Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Living DNA Ltd., Macrogen, Inc., MyHeritage Ltd., Myriad Genetics, Inc., Natera, Inc., Newtopia Inc., PathogenDx Corporation, PerkinElmer Inc., Qiagen N.V., Sanofi S.A., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Consumables & Equipment
- Software & Services

Test Type
- Carrier Testing
- Diagnostic Testing
- New Born Screening
- Pharmacogenomics
- Preimplantation Testing
- Prenatal Testing
- Presymptomatic & Predictive Testing

Technology
- Cytogenetics
- DNA Sequencing
- Gene Expression Profiling
- Microarrays
- PCR

Application
- Autoimmune Disorders
- Cancer
- Chronic Diseases
- Genetic Disorders
- Neurodegenerative Diseases

Distribution Channel
- Offline
- Online

End-User
- Diagnostic Laboratories
- Home Setting
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Genetic Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Genetic Testing Market?

3. What are the technology trends and regulatory frameworks in the Genetic Testing Market?

4. What is the market share of the leading vendors in the Genetic Testing Market?

5. Which modes and strategic moves are suitable for entering the Genetic Testing Market?

Product Code: MRR-437E9896A512

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of genetic and oncology disorders and need for precision medicine
  - 5.1.1.2. Government initiatives for genetic testing and rise of self-test kits
- 5.1.2. Restraints
  - 5.1.2.1. Concerns associated with false positives & negatives of genetic tests
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing research and new developments in genetic testing technologies
  - 5.1.3.2. Emergence of genetic testing with telehealth and digital health platforms
- 5.1.4. Challenges
  - 5.1.4.1. Logistical barriers and privacy concerns to genetic testing
5.2. Market Segmentation Analysis
- 5.2.1. Product: Penetration of software and services for efficient data management and analysis
- 5.2.2. Test Type: Emphasis on diagnostic testing to perform particular disease dignosis
- 5.2.3. Technology: Increasing shift toward DNA sequencing for precise gene identification and disease diagnosis
- 5.2.4. Application: Rising adoption of genetic testing to detect early signs of cancer
- 5.2.5. Distribution Channel: Deployment of genetic testing products on online platforms
- 5.2.6. End-User: Extensive use of genetic testing solutions in hospitals & clinics for disease diagnosis and treatment planning
5.3. Market Trend Analysis
- 5.3.1. Technological advances and presence of established pharmaceutical companies enhance the genetic testing market growth in the Americas
- 5.3.2. Increasing chronic disorders and expanding healthcare infrastructure supports genetic testing in the APAC region.
- 5.3.3. Government initiatives and increasing demand for personalized medicine expand genetic testing market growth in the EMEA region.
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis

6. Genetic Testing Market, by Product

6.1. Introduction
6.2. Consumables & Equipment
6.3. Software & Services

7. Genetic Testing Market, by Test Type

7.1. Introduction
7.2. Carrier Testing
7.3. Diagnostic Testing
7.4. New Born Screening
7.5. Pharmacogenomics
7.6. Preimplantation Testing
7.7. Prenatal Testing
7.8. Presymptomatic & Predictive Testing

8. Genetic Testing Market, by Technology

8.1. Introduction
8.2. Cytogenetics
8.3. DNA Sequencing
8.4. Gene Expression Profiling
8.5. Microarrays
8.6. PCR

9. Genetic Testing Market, by Application

9.1. Introduction
9.2. Autoimmune Disorders
9.3. Cancer
9.4. Chronic Diseases
9.5. Genetic Disorders
9.6. Neurodegenerative Diseases

10. Genetic Testing Market, by Distribution Channel

10.1. Introduction
10.2. Offline
10.3. Online

11. Genetic Testing Market, by End-User

11.1. Introduction
11.2. Diagnostic Laboratories
11.3. Home Setting
11.4. Hospitals & Clinics

12. Americas Genetic Testing Market

12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Genetic Testing Market

13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam

14. Europe, Middle East & Africa Genetic Testing Market

14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom

15. Competitive Landscape

15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
- 15.3.1. DNA company Asa Ren raises USD 8M and more briefs
- 15.3.2. Devyser launches two new genetic testing solutions for hereditary cancer
- 15.3.3. Blueprint Genetics introduces the new Screening Tests family; giving actionable insights for family planning, and future health
- 15.3.4. Kindbody Brings Genetic Testing In-House with the Launch of Kindlabs
- 15.3.5. Genetic Testing Firm Delve Gets USD 35 Million in VC Funding
- 15.3.6. FBI approves QIAGEN's NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS)
- 15.3.7. Sema4 to acquire genetic testing firm GeneDx for USD 623 Million
- 15.3.8. Scribe and Sanofi expand genetic therapy development deal
- 15.3.9. healthOme Acquires Kailos Genetics
- 15.3.10. MapMyGenome launches India's First DNA Test For Personalized Skin And Hair Care
- 15.3.11. CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
- 15.3.12. PathogenDx Expands Reach of Its Patented Multiplexed Molecular Testing Technology, Bringing It to the Clinical, Food and Agriculture Sectors
- 15.3.13. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
- 15.3.14. Invitae Announces Partnership with Epic to Streamline Genetic Testing
- 15.3.15. Grand Launching Of DNATEST.ID, A Comprehensive Dna Test In Indonesia
- 15.3.16. MyHeritage Releases cM Explainer to Predict Familial Relationships Between DNA Matches with Greater Accuracy

16. Competitive Portfolio

16.1. Key Company Profiles
16.2. Key Product Portfolio